Archive: August 4, 2026

Canara HSBC Life Insurance simplifies claims process for families affected by the Assam floods

• Simplified claim documentation to enable faster settlement for policyholders affected by the Assam floods
• Expedited assessment and settlement of eligible claims
• Dedicated District Claims Service Head to provide on-ground assistance
• Multiple claim submission channels including email, customer app and helpline for seamless support

MUMBAI, India, Aug. 4, 2026 /PRNewswire/ — Canara HSBC Life Insurance extends its deepest condolences to the families impacted by the devastating floods in Assam. During this challenging time, the Company stands in solidarity with all those affected and remains committed to supporting our policyholders in every way possible. To provide timely financial relief, we have introduced a simplified and accelerated claims settlement process, helping ensure faster access to the assistance families need most.

To ensure faster claim processing, the Company has relaxed certain documentation requirements and is prioritizing the assessment and settlement of eligible claims, enabling affected families to receive financial assistance at the earliest possible.

Claimants can submit the following documents to process their claims:

• Death Certificate issued by Municipal Authorities; or list of deceased persons published by State/Central Government authorities; or any other acceptable proof of death, as applicable.
• Claimant Statement / Claim Form.
• Photo identity proof of the claimant along with proof of relationship to the Life Assured, wherever applicable.
• Bank account details of the claimant, including a cancelled cheque, bank statement or NEFT mandate.

The claimants can also submit the above through any of the following channels:

• Email: claims.unit@canarahsbclife.in
• Email: customerservice@canarahsbclife.in
• Canara HSBC Life Insurance Customer App
• Customer Care Helpline: 1800-891-0003 | 1800-103-0003

In case of any requirement of personalised support, policyholders may reach out to the Company’s dedicated District Claims Service Head:

Mr. Pankaj Das

Mobile: +91 98592 84460

Email: pankaj.das@canarahsbclife.in

Canara HSBC Life Insurance remains committed to supporting affected policyholders and their families by ensuring compassionate assistance and prompt settlement of eligible claims during this challenging time.

About Canara HSBC Life Insurance

Incorporated in 2007, Canara HSBC Life Insurance Company Limited is a joint venture promoted by Canara Bank (36.5 per cent) and HSBC Insurance (Asia Pacific) Holdings Limited (25.5 per cent). As a bancassurance-led publicly listed insurance company with its corporate office at Gurugram, Haryana and 107 branch offices as of June 30, 2026, pan India, Canara HSBC Life brings together the trust and market knowledge of public and private banks.

For 18 years now, Canara HSBC Life Insurance has sold insurance products to customers through multiple channels and a well-diversified network of Canara Bank, HSBC Bank and its other bancassurance partners located in multiple Tier 1, 2 and 3 cities across the country. Canara HSBC Life Insurance has a vast portfolio of life insurance solutions and offers various products across individual and group spaces comprising of life, term plans, retirement solutions, credit life and employee benefit segments through partner banks and digital channels.

With an aim to provide simpler insurance and faster claim process, Canara HSBC Life Insurance intends to keep the promises of their customers alive with their ‘Promises Ka Partner’ philosophy.

View original content to download multimedia:https://www.prnewswire.com/in/news-releases/canara-hsbc-life-insurance-simplifies-claims-process-for-families-affected-by-the-assam-floods-302842175.html

Jo Malone London Launches Sea Salt & Bergamot, the ‘scent of a new adventure’

LONDON, Aug. 4, 2026 /PRNewswire/ — Plunge into the exhilarating surf of the Celtic Sea. Immersed in the wild waters, every wave carries a fresh minerality. Joining a burst of bergamot, driftwood accord anchors this sea salt-fresh scent. Experience the untamed beauty of the British coast.

Introducing Sea Salt & Bergamot, the new fresh and woody cologne by Jo Malone London. In the same boat as Wood Sage & Sea Salt, it builds on the brand’s selection of sea salt-fresh scents inspired by the British coast. While Wood Sage & Sea Salt is set on the windswept shore, Sea Salt & Bergamot is immersed in the wild waters. Customers are invited to discover the stimulating new cologne and explore the edit in-store and online.

Perfumer: Mathilde Bijaoui

Top: Bergamot

Heart: Sea Salt

Base: Driftwood

Sea Salt & Bergamot Cologne will be available online at jomalone.co.uk and in Jo Malone London stores from August 2026. Follow Jo Malone London on TikTok, Instagram, Facebook, X, YouTube, LinkedIn and Pinterest: @JoMaloneLondon #JoMaloneLondon #ScentsOfBritain

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/jo-malone-london-launches-sea-salt–bergamot-the-scent-of-a-new-adventure-302841338.html

Piramal Pharma Solutions Expands Peptide API Facility with Advanced Spray Drying Suite

• Piramal Pharma Solutions has added a new spray drying suite with Band 5 containment capacity at its dedicated peptide facility in Turbhe, India, equipped with its own air handling units, nitrogen supply, and control systems.
• The new suite empowers Turbhe to support the formulation of challenging molecules, including peptides, HPAPIs, and other biomolecules.

MUMBAI, India, Aug. 4, 2026 /PRNewswire/ — Piramal Pharma Solutions (“PPS”), a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), has launched a state-of-the-art spray drying suite at its dedicated peptide development and manufacturing facility in Turbhe, India. This strategic expansion enables PPS to address the complex formulation challenges associated with peptides and other complex molecules and support the growing demand for these innovative molecules.

Spray drying transforms liquid formulations into dry powders in a single step, enabling drug developers to enhance bioavailability, achieve precise particle size, and process sensitive compounds safely. This technique is especially critical for peptides, which are unstable at high temperatures and often require strict control over particle properties. Its gentle and efficient nature enables drug developers to improve solubility, streamline scale-up, and increase speed, all while preserving the molecular integrity of their peptide API.

The new spray drying suite operates as a closed-loop system, equipped with its own inert gas supply and advanced safety measures, including specialized HVAC, airlocked entries and exits, operator isolation, and a dedicated cleaning area. This enables the safe handling of potent compounds and organic solvents requiring up to Band 5 containment. To further strengthen these capabilities, the processing area maintains ISO Class 8 (Class 100,000) cleanliness standards, ensuring strict control of the environment throughout operations.

Engineered for small-volume, high potency batches, the unit supports a feed rate of up to 1 liter per hour. It can spray dry highly concentrated solutions — even those with up to 30% water content — making it particularly valuable for the formulation of biomolecules and large peptides. Under optimal conditions, the suite can also be leveraged for low-volume small-molecule formulations.

“Peptides present some of the most intricate formulation challenges in pharmaceutical development, owing to their inherent instability and sensitivity to processing conditions,” said Dr. Jordi Bacardit, Global Technical Lead on Peptides and Member of the Science Collective at PPS. “Spray drying addresses these distinct challenges by allowing tight control over key components like temperature and solvent environment. With the addition of the spray drying suite at Turbhe, we can help our partners bring stable, high-quality peptide formulations to patients in need worldwide.”

With peptides and other complex molecules playing an increasingly vital role in modern pharmaceuticals, this spray drying expansion further positions PPS as a trusted partner across a broad range of therapeutic areas.

About Piramal Pharma Solutions

Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our customers through a globally integrated network of facilities in North America, Europe, and Asia. This enables us to offer a comprehensive range of services including drug discovery solutions, process and pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms. We also offer specialized services such as the development and manufacture of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited’s associate company, Yapan Bio Private Limited.

For more information visit: Piramal Pharma Solutions | LinkedIn | Facebook | X

About Piramal Pharma Limited

Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17* global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the Piramal Consumer Healthcare business, selling over-the-counter consumer and wellness products. In addition, one of PPL’s associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics / bio-therapeutics and vaccine segments.

For more information, visit: Piramal Pharma | LinkedIn

* Includes one facility via PPL’s minority investment in Yapan Bio.

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/piramal-pharma-solutions-expands-peptide-api-facility-with-advanced-spray-drying-suite-302842218.html

Indusface Introduces SwyftComply AI, Defining the Next Era of Application Security with Autonomous Vulnerability Remediation

As AI transforms vulnerability discovery from weeks to minutes, SwyftComply AI enables enterprises to protect applications just as quickly through autonomous virtual patching, expert validation and SLA-backed remediation.

BENGALURU, India, Aug. 4, 2026 /PRNewswire/ — Indusface, the leading application security company trusted by enterprises to protect thousands of applications and APIs globally, today announced SwyftComply AI, an autonomous vulnerability remediation solution that virtually patches vulnerabilities surfaced by AI-assisted pentesting.

Artificial Intelligence has fundamentally changed the economics of application security. AI-powered security agents now uncover exponentially more vulnerabilities than ever before. Yet remediation has not accelerated. Security teams are overwhelmed by findings while remediation remains constrained by engineering bandwidth. The cybersecurity industry has entered a new phase: the race has moved from finding vulnerabilities to protecting applications before they’re exploited. Indusface believes the industry must move beyond AI-assisted testing toward Autonomous Vulnerability Remediation.

“AI has made vulnerability discovery dramatically faster. The next challenge for the industry is autonomous vulnerability remediation. SwyftComply AI helps enterprises keep pace with AI-driven threats without overwhelming development teams,” said Ashish Tandon, Founder and CEO, Indusface.

SwyftComply AI delivers four connected outcomes:

1. AI-Assisted Discovery: Multi-model pentesting uncovers 5 to 10 times more critical and high-severity vulnerabilities compared to traditional approaches.
2. Autonomous Virtual Patching: Virtual patches deploy at the edge automatically, with no code changes or release windows required.
3. Human-Certified Validation: Indusface security experts verify remediation within an SLA and guarantee zero false positives.
4. Continuous Compliance: Every cycle closes with an expert-verified vulnerability remediation report enterprises can present to their boards and regulators.

For more than a decade, Indusface has focused on reducing the time between vulnerability discovery and protection. SwyftComply AI extends that vision into the AI era.

“The AI era is uncovering business-logic vulnerabilities faster than most security teams can respond. That gap is widening across sectors. Our evaluation of SwyftComply AI showed exactly what enterprises need: vulnerabilities closed as fast as they’re found, and a report auditors can trust,” said Vinayak Godse, CEO, Data Security Council of India (DSCI).

“AI-assisted pentesting surfaces vulnerabilities far faster than any development calendar can absorb. With SwyftComply AI, findings are patched at the edge as they arrive, allowing our development teams to remediate root causes through their normal release cycles instead of constantly reacting to newly discovered vulnerabilities. That enables us to strengthen security without slowing business delivery,” said Nishith Kumar Datta, Head of Information Security, Titan Company Limited.

SwyftComply AI is available immediately. Existing AppTrana customers can upgrade through their account teams, while new customers can onboard to the platform directly. Once live, organizations can virtually patch vulnerabilities, whether surfaced by Indusface, their own VA/PT, or red-team engagements, with vulnerabilities patched and a clean report provided within SLA. Request a demo here.

About Indusface

Indusface secures the web, API, and AI applications of thousands of organizations across 95 countries. Backed by leading institutional investors, Indusface is recognized by Gartner, Forrester, and IDC for its innovation in application security and meets globally accepted security and compliance standards, including ISO 27001, SOC 2, PCI DSS, and GDPR. Its globally distributed cloud infrastructure spans Asia, the Middle East, Europe, and North America, enabling low-latency protection and regional data residency for enterprises worldwide.

AppTrana is Indusface’s autonomous enterprise application security platform that continuously discovers vulnerabilities, autonomously remediates exploitable risks through virtual patching, and protects applications against DDoS, bot, API, AI, and zero-day attacks. Combining AI-powered intelligence, expert governance, and SLA-backed protection, AppTrana helps organizations reduce the time from vulnerability discovery to protection while delivering compliance-ready reports with zero false positives.

Media Contact:

Phani Akella

phani.akella@indusface.com 

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/indusface-introduces-swyftcomply-ai-defining-the-next-era-of-application-security-with-autonomous-vulnerability-remediation-302842227.html